
|Articles|July 27, 2020
Montrium’s eTMF Connect Solution Used in Global Phase III PTSD Study
Advertisement
Montrium, a provider of cloud-based software solutions for the life sciences, announced its eTMF Connect trial master file solution is being used in a Phase III global post-traumatic stress disorder (PTSD) trial. The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research organization is advancing from its MAPP1, the first study carried out in Phase III, to a global confirmatory MAPP2 study to assess the safety and efficacy of MDMA-assisted psychotherapy for patients with PTSD.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain
2
Moving Beyond Historical Site Data to Real-Time Patient Insight
3
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
4
How Community Sites Can Stay Competitive Under Growing Efficiency Pressures
5



